ClinicalTrials.gg
CompletedNCT06192264Updated Jun 19, 2025

A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris

A Phase 3 interventional study of ASC40 in Acne, sponsored by Ascletis Pharmaceuticals Co., Ltd.. Completed at 41 sites in China. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-06-19.

Sponsored by Ascletis Pharmaceuticals Co., Ltd. (part of Ascletis Pharma Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Acne Vulgaris with a site in China — 8 open to participants now, 10 under way, 2 of them phase 3. Acne Vulgaris · China.

Enrollment
6th of 33
480 · median 100
Started
2024
with 4 others
Phase 3
8 of 35
1 open now
Registered
19th of 35
by date
Lead sponsor
3 of 35
Ascletis Pharmaceuticals Co., Ltd.

Among the 35 studies in Acne Vulgaris with a site in China, this one is the 6th largest by enrollment of the 33 interventional ones that give a count, is one of 5 that started in 2024, is one of 8 in phase 3, and was the 19th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

8 of the 35 studies in Acne Vulgaris with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Acne Vulgaris with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of ASC40 (Denifanstat) tablets compared to placebo in the treatment of patients with moderate to severe acne vulgaris. The proposed plan for this trial is to enroll subjects who are 18-40 years of age (including borderline values), with a diagnosis of moderate to severe acne vulgaris, and an Investigator's Global Assessment (IGA) graded as moderate (grade 3) or severe (grade 4). 480 subjects were planned to be enrolled in the trial and placebo groups, with all subjects randomly assigned in a 1:1 ratio to receive either ASC40 (denifanstat) tablets dose 1 or placebo, administered orally once daily (taken after dinner) for 12 weeks.

There will be a total of 6 visits for screening and follow-up. The tests required by the program included routine blood tests, blood biochemistry, lipid profile, pregnancy test and urine routine, etc..

03

Conditions studied

  • Acne

Browse trials for

Keywords

  • Acne
  • ASC40
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-40 years (inclusive of threshold), gender is not limited.
  • Subjects have an Investigator's Global Assessment (IGA) score of 3 or 4 (i.e., moderate or severe).
  • Men of and women of childbearing potential willing to use effective from the time of signing the until 3 months after the last dose of the drug; women of childbearing potential include premenopausal women and women within 2 years of menopause. Women of childbearing potential must have a negative pregnancy test result within ≤ 7 days prior to the first dose of the investigational drug.
  • Subjects are willing and able to complete the study, are able to understand and comply with the study requirements, adhere to the study required restrictions and related tutorials, use the investigational drug as prescribed, and are followed up according to the study plan.

Exclusion criteria

Exclusion Criteria:

  • Known to the ingredients of ASC40 (Denifanstat) tablets or to any of the .
  • Presence of cystic acne at screening.
  • Patients with secondary acne such as occupational acne (e.g., chloracne) and -induced secondary acne (e.g., chloracne or drug-induced acne)
  • Patients with other significant coexisting skin conditions that may affect the evaluation of facial acne efficacy or require co-treatment, such as solardermatitis, psoriasis, seborrheic dermatitis, rosacea, folliculitis, eczema, etc..
  • Thicker facial hair, which has been assessed by researchers to impede accurate assessment of acne vulgaris grades or lesion counts
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
480 participants (actual)

Study arms

  • Experimental
    ASC40 dose 1

    ASC40 dose 1 84 days of treatment

    Drug: ASC40

  • Placebo comparator
    ASC40 Placebo

    ASC40 Placebo 84 days of treatment

    Drug: ASC40

Interventions

  • DrugASC40

    ASC 40 tablets orally once daily

06

What researchers measure

Primary outcomes

  1. Percentage of treatment success based on investigator's global assessment (IGA) in each group of subjects

    Percentage of treatment success subjects in each group based on investigator's global assessment (IGA) at Week 12 (treatment success defined as an IGA grade of 0 or 1, and a ≥2-grade decrease in IGA grade from baseline)

    Time frame: At Week 12 of treatment.

  2. Percentage change in total skin lesion counts compared to baseline ineach group of subjects

    Percentage change in total skin lesion counts compared to baseline for subjects in each group at Week 12

    Time frame: At Week 12 of treatment.

  3. Percentage change in the count of inflammatory skin lesions compared to baseline in each group of subjects

    Percentage change in inflammatory skin lesion counts compared to baseline for subjects in each group at Week 12

    Time frame: At Week 12 of treatment.

Secondary outcomes

  1. Percentage change in non-inflammatory lesion counts compared to baseline for each group of subjects

    Percentage change in non-inflammatory lesion counts compared to baseline for subjects in each group at Week 12

    Time frame: At Week 12 of treatment.

  2. Absolute change in total skin lesion counts compared to baseline for each group of subjects

    Absolute change in total skin lesion counts compared to baseline for each group of subjects at Week 12

    Time frame: At Week 12 of treatment.

  3. Absolute change in inflammatory skin lesion counts compared to baseline in each group of subjects

    Absolute change in inflammatory skin lesion counts compared to baseline in each group of subjects at Week 12

    Time frame: At Week 12 of treatment.

07

Study locations

41 sites
  • The First Affiliated Hospital of Bengbu Medical University
    Bengbu, Anhui, China
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
  • The First Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui, China
  • The Second Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui, China
  • Beijing Tsinghua Changgeng Hospital
    Beijing, Beijing, China
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian, China
  • Dermatology Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong, China
  • The Fifth Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
  • Shenzhen Hospital, The University of Hong Kong
    Shenzhen, Guangdong, China
  • The Affiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong, China
  • Guilin Medical College Affiliated Hospital
    Guilin, Guangxi, China
  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Guangzhou, Guangzhou, China
  • Shenzhen People's Hospital
    Shenzhen, Guangzhou, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
  • Nanyang First People's Hospital
    Nanyang, Henan, China
  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Wuhan Central Hospital
    Wuhan, Hubei, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan, China
  • Changzhou First People's Hospital
    Changzhou, Jiangsu, China
  • Lianyungang First People's Hospital
    Lianyungang, Jiangsu, China
  • The First Affiliated Hospital of Gannan Medical College
    Ganzhou, Jiangxi, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • Huashan Hospital Fudan University
    Shanghai, Shanghai 200000, China
  • Shanghai Skin Disease Hospital
    Shanghai, Shanghai, China
  • The First Affiliated Hospital of Xi'an Medical College
    Xi'an, Shanxi, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University School of Medicine
    Xi'an, Shanxi, China
  • Chengdu Second People's Hospital
    Chengdu, Sichuan, China
  • Suining Central Hospital
    Suining, Sichuan, China
  • Tianjin Medical University General Hospital
    Tianjing, Tianjing, China
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang, China
  • Hangzhou Third People's Hospital
    Hangzhou, Zhejiang, China
  • Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Ningbo Second Hospital
    Ningbo, Zhejiang, China
  • The First Affiliated Hospital of Ningbo University
    Ningbo, Zhejiang, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
  • The Fourth Affiliated Hospital of Zhejiang University School of Medicine
    Yiwu, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in May 2025, 15 months.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 15 months is above that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2023
First posted
Jan 5, 2024
StartActual
Jan 23, 2024
Primary completionActual
May 19, 2025
CompletionActual
May 19, 2025
Last update
Jun 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06192264
Responsible party
Sponsor
First posted
Jan 5, 2024
Start date
Jan 23, 2024
Primary completion
May 19, 2025
Completion
May 19, 2025
Last update
Jun 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TVB-2640

Start the discussion